Toshiba TEC and Stratas join forces to make a valuable donation to Bowel Cancer UK
Toshiba TEC, the leading imaging solutions provider, has announced that one of its innovative e-STUDIO2550CSE Multifunction Products (MFPs), worth £13,000, has been donated to Bowel Cancer UK, a charity that raises awareness of the disease and provides information and support for those affected by it.
Every year 41,500 people are diagnosed with bowel cancer, which equates to one diagnosis every 15 minutes, and around 16,000 people die of the disease. It is the fourth most common cancer in the UK behind breast, lung and prostate, and the lifetime risk of developing bowel cancer in the UK is one in 14 for men and one in 19 for women.
Bowel Cancer UK was chosen as a worthy recipient of the Toshiba e-STUDIO2550CSE colour device, after being nominated at this year’s Charity IT Leaders (CITL) Conference, at which Toshiba TEC’s technology partner, Stratas, supplied an MFP to allow delegates to print to from their mobile devices during the conference. Rob Holyoake, Director at Stratas, explained, ‘At the end of the event we decided that we would like to donate the MFP to a charity and selected a number of speakers at the event to nominate a charity. Ian Williamson, ICT Director at UNICEF UK, gave a very moving speech about bowel cancer for which all of the delegates attending agreed that Bowel Cancer UK should be the charity to receive this product because they felt it would really make a difference to them.’
For 27 years Bowel Cancer UK has been aiming to save lives and improve the quality of life for all those affected by bowel cancer. The charity’s Corporate Partnership’s Executive, Natasha Romain, commented, ‘As a charitable organisation, we are almost completely dependent on voluntary donations. Therefore, having a state-of-the-art piece of office equipment given to us was an enormous surprise and we are incredibly grateful to Toshiba TEC and Stratas.’
Stratas is a leader in understanding and extracting intelligence from physical and digital document landscapes (a company’s “Information Backbone”) to deliver step changes in process optimisation and governance. Rob Holyoake, explains, ‘ We work closely with Toshiba TEC to drive innovation for all our clients and, by combining our extensive expertise, we can ensure that our customers are able to achieve the highest levels of operational efficiency’. Stratas has already installed the e-STUDIO2550CSE at Bowel Cancer UK’s London headquarters and the MFP has been specified to meet the organisation’s requirements with features such as confidential printing and Secure Erase Drive (SED) technology that makes unauthorised access to information impossible with Toshiba’s unique self-encrypting hard disk drive technology. Employees have also been given tutorials about how to maximise the potential of the device so that energy use and paper waste can be reduced.
As an environmentally aware organisation, Bowel Cancer UK does all it can to reduce its carbon emissions, so it was pleased to find out that the e-STUDIO2550CSE is part of Toshiba TEC’s pioneering Carbon Zero scheme which ensures that any CO2 produced during the manufacture and supply of the company’s MFPs is entirely offset. This is done through a range of initiatives coordinated by co2balance, the leading global carbon management company, such as helping villagers in Kenya reduce their use of wood for fuel by building highly efficient stoves. co2balance also provides an on-going sustainability report for each customer including GPS tagging and annual programme audits to see exactly how their Carbon Zero MFP is making a difference to some of the world’s poorest communities.
Assessing the impact that the e-STUDIO2550CSE has had on Bowel Cancer UK’s administrative function, Natasha Romain concluded, ‘It has made an overwhelmingly positive difference to our resources. Everyone has commented on how easy it is to use and knowing that we have such a reliable machine in the office allows us to concentrate on the important work we are doing in raising awareness of bowel cancer.’
Tags:
